[Form 4] Albemarle Corporation Insider Trading Activity

Rhea-AI Filing Summary

Medicus Pharma Ltd. (Nasdaq: MDCX) has filed Prospectus Supplement No. 6 to its May 29, 2025 prospectus in connection with the potential resale of up to 3,710,000 common shares. The supplement attaches Amendment No. 1 to the Company’s June 30, 2025 Current Report, which formally files and incorporates by reference a Share Exchange Agreement dated June 29, 2025 among Medicus, Antev Limited and Antev security-holders.

The Agreement—filed as Exhibit 2.1—sets out the framework for a contemplated transaction involving Antev and the oncology/uro-oncology candidate Teverelix. While financial terms remain redacted, management states that the deal is expected to advance and commercialize Teverelix and open new market opportunities. The filing does not amend any other disclosures contained in the original 8-K.

The Company reiterates its emerging-growth-company status and reminds investors to review the “Risk Factors” section beginning on page 9 of the original prospectus. Shares continue to trade on the Nasdaq Capital Market; the most recent closing price (July 2, 2025) was $3.22.

No updated financial statements or pro-forma data are included in this supplement. Investors should therefore focus on potential dilution from the 3.71 million shares and on execution risks surrounding the Antev transaction, which is still subject to customary conditions.

Positive

• Filing of the Share Exchange Agreement increases transparency and moves the Antev transaction forward procedurally.
• Potential strategic upside from Antev’s Teverelix asset if development and commercialization milestones are met.
• Company maintains Nasdaq listing with recent share price disclosure, supporting liquidity.

Negative

• Registration covers up to 3.71 million shares, creating potential dilution and market overhang.
• Exhibit is redacted; investors still lack critical financial terms of the Antev exchange, limiting valuation analysis.
• Forward-looking statements underscore significant regulatory, development and market risks with no updated financial guidance.

Insights

M&A Specialist

TL;DR – Amendment simply files the Antev Share Exchange Agreement; no valuation or closing certainty yet, so market impact is limited.

The inclusion of the Agreement satisfies SEC requirements and adds transparency, but investors still lack visibility on consideration, earn-outs or integration timelines. Because the exhibit is heavily redacted, it is impossible to assess dilution versus strategic upside. Until definitive closing or financial metrics emerge, I view the disclosure as procedural rather than catalytic.

Securities Analyst

TL;DR – Share resale ceiling of 3.71 M shares could pressure MDCX (~$12 M at last price) but overall disclosure is neutral.

At $3.22, the registered shares equate to roughly 11 percent of the company’s equity market value, posing potential dilution overhang. However, no new financing terms are announced and the supplement merely aligns prior filings. The forward-looking commentary on Teverelix suggests strategic intent, yet execution risk remains. I assign a neutral impact pending additional data.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Deursen Holly

(Last) (First) (Middle)

ALBEMARLE CORPORATION

4250 CONGRESS STREET, SUITE 900

(Street)

CHARLOTTE NC 28209

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALBEMARLE CORP [ ALB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock	(1)	07/01/2025		A		2,725(2)		(3)	(4)	Common Stock	2,725	$0	8,692(5)	D

Explanation of Responses:

1. Phantom Stock units convert 1 for 1 into common stock.

2. Phantom Stock units represent an annual award of non-employee director stock compensation issued under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors of Albemarle Corporation (the "2023 Directors Plan"). Units to vest on July 1, 2026.

3. Payable as shares of common stock upon events established by the reporting person in accordance with the terms of the 2023 Directors Plan.

4. No expiration date.

5. Includes dividend equivalent rights earned based on total shares of Phantom Stock in reporting person's deferred stock account.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Rebekah Richards, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Medicus Pharma (MDCX) shares are covered by Prospectus Supplement No. 6?

The supplement registers the potential resale of up to 3,710,000 common shares.

What new document was filed with this prospectus supplement?

Medicus attached the Share Exchange Agreement dated June 29, 2025 between Medicus, Antev Limited and Antev security-holders.

Does the filing disclose financial terms of the Antev transaction?

No. Key portions are redacted under Regulation S-K; valuation and consideration details are not provided.

What was the last reported MDCX share price before the filing?

On July 2, 2025, Medicus Pharma’s common shares closed at $3.22 on Nasdaq.

Why is Medicus classified as an emerging growth company?

Under SEC rules, emerging growth companies benefit from reduced disclosure requirements, which Medicus has opted to use.